Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World

  • Posted by: Biocon Biologics

Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

  • Posted by: Biocon Biologics

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20%

  • Posted by: Biocon Biologics

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

  • Posted by: Biocon Biologics

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

  • Posted by: Biocon Biologics

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics’ Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases

  • Posted by: Biocon Biologics

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Foundation Supports Government High School, Kicks off Construction of a New Building for 250 Students

  • Posted by: Biocon Biologics

U.S. FDA Completes Inspection at Biocon Biologics’ Facility at Biocon Campus, Bengaluru, India

  • Posted by: Biocon Biologics
Share